Furthermore, epigenetic modification in both Keap1 and Nrf2 can also activate Nrf2 as demonstrated in malignant glioma, colon cancer, and breast cancer (Muscarella et al., 2011; Hanada et al., 2012; Barbano et al., 2013). This evidence concerns the gene NFE2L2 and breast cancer.